Tuesday, November 04, 2008




Osiris Leaps on $1.38 Billion Genzyme Stem-Cell Deal (Update1)
By Elizabeth Lopatto
Nov. 4 (Bloomberg) -- Osiris Therapeutics Inc. rose the most in 19 months in Nasdaq Stock Market trading after Genzyme Corp. agreed to pay the company as much as $1.38 billion to develop two experimental drugs using adult stem cells.

... the other Osiris un-nefer ...
:)


Labels:






<< Home

This page is powered by Blogger. Isn't yours?

Subscribe to Posts [Atom]